NCT00045695View on ClinicalTrials.gov

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

March 31, 2006

Study Completion Date

December 31, 2009

Conditions
Lymphoma
Interventions
DRUG

bortezomib

PS-341 bolus intravenous injection twice weekly\* for 2 out of every 3 weeks

Trial Locations (12)

60521

Hinsdale Hematology Oncology Associates, Hinsdale

19104-4283

Abramson Cancer Center at the University of Pennsylvania, Philadelphia

T2N 4N2

Tom Baker Cancer Centre - Calgary, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

Nova Scotia Cancer Centre at Queen Elizabeth II Health Sciences Centre, Halifax

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Eastern Cooperative Oncology Group

NETWORK

lead

NCIC Clinical Trials Group

NETWORK